Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.36 |
| ▸ | DRD2 | P14416 | 6/20 | 0.35 |
| ▸ | DRD3 | P35462 | 4/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | FABP7 | O15540 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21151293 | 0.88 | TACR1 (0.34) | HRH4DRD2DRD3TACR1PIK3CA | |
| SCHEMBL24974746 | 0.77 | NPY5R (0.37) | FABP7 | |
| SCHEMBL21150938 | 0.76 | DRD2 (0.34) | HRH4DRD2DRD3TACR1KMT2A | |
| SCHEMBL24974609 | 0.73 | FABP7 (0.40) | DRD2DRD3TACR1FABP7KMT2A | |
| SCHEMBL21151318 | 0.71 | TACR1 (0.44) | HRH4TACR1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL24974548 | 0.70 | KMT2A (0.37) | TACR1FABP7KMT2A | |
| SCHEMBL24974366 | 0.70 | KDM4E (0.42) | TACR1KMT2A | |
| SCHEMBL24974772 | 0.68 | AKT1 (0.40) | TACR1FABP7 | |
| SCHEMBL21151335 | 0.67 | LIPG (0.32) | DRD2DRD3TACR1FABP7 | |
| SCHEMBL24974551 | 0.67 | KDR (0.43) | FABP7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | HRH4 2308/4885DRD2 1684/4885DRD3 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.